Baliopharm / Company Profile
Superior antibody therapeutics with enhanced safety profiles
Our mission is to develop novel therapeutics with increased target selectivity for the treatment of acute and chronic diseases.
Baliopharm AG is a biotechnology company focusing on the development of innovative therapeutics for the treatment of chronic liver diseases, immune mediated inflammatory diseases, as well as for cancer. Our portfolio consists of monoclonal antibodies and antibody derived proteins like monovalent formats and bispecifics with unique target selectivity.
Baliopharm was founded in 2006 as Celonic AG, a service company for the contract development and manufacturing of biopharmaceutical compounds, based on the operations founded 1998 in Germany (Celonic GmbH). In 2009, Celonic started to develop its own therapeutic proteins for the treatment of cancer and autoimmune diseases. In late 2011, the service unit was sold to Josef Rettenmaier & Söhne and the remaining operations focused on the development of therapeutic antibodies renamed to Baliopharm AG.
In 2018, Baliopharm was acquired by Promethera Biosciences to enlarge their portfolio of cell-based therapies for the treatment of a broad variety of liver diseases [Link press release]. Independently of the acquisition, Baliopharm continues to pursue the development of its oncology assets.